Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue 
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market 
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge 
BP Nears $10 Billion Castrol Stake Sale to Stonepeak 
Nvidia and Groq Strike Strategic AI Inference Licensing Deal 
Winter Storm Devin Triggers Massive Flight Cancellations and Travel Disruptions Across the U.S. 
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling 
California DMV Proposes New Safety Rules for Autonomous Vehicles After Waymo Incidents 
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy 
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants 
TSMC Honors Japanese Chip Equipment Makers With 2025 Supplier Awards 
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement 
Brazilian Oil Workers’ Strike Continues as Key Petrobras Union Rejects Proposal 
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies 
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio 
CAMBRIDGE, Mass., Feb. 15, 2017 -- Intellia Therapeutics, Inc. (Nasdaq:NTLA) will hold a conference call with investors on Thursday, February 16, 2017 at 8 a.m., EST. Investors are invited to dial into the conference call hosted by Nessan Bermingham, Ph.D., chief executive officer and founder, Jose E. Rivera, executive vice president and general counsel, and Graeme Bell, chief financial officer.
To participate on the day of the call, dial 844-882-7840 and use Conference ID# 74650186, approximately five minutes before the call. International callers, please dial +1 574-990-9827 and use Conference ID# 74650186.
The call will be available for replay from February 16 to March 18, 2017. The replay number is 855-859-2056, Conference ID# 74650186. International callers, please dial +1 404-537-3406, Conference ID# 74650186.
About Intellia Therapeutics
Intellia Therapeutics is a leading genome editing company, focused on the development of proprietary, potentially curative therapeutics using the CRISPR/Cas9 system. Intellia believes the CRISPR/Cas9 technology has the potential to transform medicine by permanently editing disease-associated genes in the human body with a single treatment course. Our combination of deep scientific, technical and clinical development experience, along with our leading intellectual property portfolio, puts us in a unique position to unlock broad therapeutic applications of the CRISPR/Cas9 technology and create a new class of therapeutic products. Learn more about Intellia Therapeutics and CRISPR/Cas9 at intelliatx.com; Follow us on Twitter @intelliatweets.
Media Contact: Jennifer Mound Smoter Senior Vice President, External Affairs & Communications (857) 706-1071 [email protected] Investor Contact: Graeme Bell Chief Financial Officer +1 857-706-1081 [email protected]
